Metabolic Intervention for Enhanced Ferroptosis and Cuproptosis in Tumors

Study Background and Research Question

Ferroptosis and cuproptosis are two mechanistically distinct forms of regulated cell death (RCD) with emerging relevance in oncology research. Ferroptosis is characterized by iron-dependent lipid peroxidation, while cuproptosis is a copper-induced process involving mitochondrial enzyme aggregation and proteotoxic stress. As both pathways contribute to the suppression of malignant cell proliferation, there is growing interest in strategies that can activate them synchronously to maximize anti-tumor efficacy. However, achieving precise and simultaneous sensitization of tumor cells to both ferroptosis and cuproptosis has remained a significant challenge, largely due to the limitations of copper ionophores—such as poor tumor selectivity, rapid clearance, and potential off-target toxicity (paper). The central research question addressed in the reference study is: Can a metabolic intervention strategy be engineered to reinforce tumor cell susceptibility to both cuproptosis and ferroptosis, thereby enhancing anti-tumor immunity and overcoming delivery limitations of traditional copper-based therapies?

Key Innovation from the Reference Study

The study by Zhang et al. presents a novel nanosystem—designated SCu/L—that integrates a glycolysis and NAD+ metabolism inhibitor (STF-31) within a copper-tannic acid (Cu-TA) network encapsulated in lipid bilayers. This platform achieves synchronized metabolic modulation, targeting the vulnerabilities of tumor cell energy metabolism and redox regulation, which are tightly linked to the mechanisms of both ferroptosis and cuproptosis (paper). The core innovation lies in the dual-mode action of the nanosystem: it delivers copper directly into tumor mitochondria while simultaneously inhibiting cellular glycolysis and compensatory NAD+ metabolism. This approach not only increases mitochondrial copper accumulation—a requirement for cuproptosis—but also disrupts glutathione (GSH) synthesis and copper efflux, sensitizing cells to both copper- and iron-mediated cell death. The intervention further modulates the tumor immune microenvironment (TIME) and potentiates anti-tumor immunity through immunogenic cell death (ICD).

Methods and Experimental Design Insights

To operationalize this strategy, the research team synthesized a composite nanosystem by embedding STF-31 within a Cu-TA network and encapsulating it in liposomes. Key methodological steps included:

• Preparation of Cu-TA nanoparticles by coordinating copper ions with tannic acid.
• Incorporation of STF-31, a selective glucose transporter (GLUT1) inhibitor that also impairs NAD+ salvage pathways, into the nanoparticle matrix.
• Liposome encapsulation to enhance tumor targeting and improve in vivo stability.

The SCu/L nanosystem was characterized through physicochemical analysis (particle size, zeta potential, encapsulation efficiency) and tested in vitro and in vivo:

• In vitro assays: Measurements of intracellular glucose, NAD+, NADPH, ATP, GSH, and copper content in tumor cells; cell viability and death pathway markers (ferroptosis, cuproptosis, and apoptosis assays).
• In vivo efficacy: Evaluation in tumor-bearing mouse models, including assessment of tumor growth inhibition, copper accumulation, GSH depletion, and immune microenvironment remodeling.

Mechanistic readouts included mitochondrial copper aggregation (confirming cuproptosis), iron-sulfur cluster disruption, and ICD marker expression, providing robust evidence for the dual RCD activation mechanism.

Core Findings and Why They Matter

The SCu/L nanosystem produced several notable effects (paper):

• Significant reduction in intracellular glucose, NAD+/NADPH, and ATP levels, consistent with glycolytic inhibition.
• Suppression of Cu-ATPase activity, leading to impaired copper efflux and increased mitochondrial copper accumulation—a prerequisite for cuproptosis.
• GSH depletion, which sensitizes cells to lipid peroxidation and ferroptosis.
• Concurrent activation of both cuproptosis and ferroptosis, as evidenced by molecular and cellular markers.
• Remodeling of the tumor immune microenvironment, characterized by increased T-cell infiltration and ICD, resulting in enhanced anti-tumor immunity.

This concerted metabolic intervention overcomes the historical limitations of copper ionophores by ensuring tumor-selective delivery, sustained mitochondrial copper localization, and simultaneous impairment of key metabolic and redox defense pathways. The dual activation of cuproptosis and ferroptosis offers a promising approach to surmount tumor resistance mechanisms and improve the efficacy of RCD-based cancer therapies.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on metabolic intervention and iron chelation strategies in oncology:

• "DeferoxamineB: Metabolic Modulation for Advanced Cancer Research" discusses the mechanistic utility of Deferoxamine (DeferoxamineB) as a precise metabolic modulator in ferroptosis and cuproptosis studies, emphasizing its role in iron chelation and redox regulation. This aligns with the reference study's focus on targeting metabolic vulnerabilities to sensitize cancer cells to RCD.
• "Metabolic Enhancement of Ferroptosis and Cuproptosis in Tumors" offers a perspective on metabolic intervention strategies, bridging the mechanistic findings of the reference study with actionable workflows for regulated cell death-based therapy.
• "DeferoxamineB in Antitumor Immunity: Iron Chelation Meets Cell Death" expands on the immunometabolic synergy achieved by integrating iron chelation with RCD induction—concepts that are operationalized in the dual ferroptosis/cuproptosis activation strategy described by Zhang et al.

These resources underscore the importance of integrating iron metabolism modulators (such as DeferoxamineB) and metabolic inhibitors into cancer research protocols to dissect the interplay between cell death pathways and tumor immunity.

Limitations and Transferability

While the SCu/L nanosystem demonstrates robust preclinical efficacy, key limitations remain:

• Translation to clinical settings: The nanosystem has thus far been validated in cell and animal models. Its pharmacokinetics, long-term safety, and tumor selectivity in humans require further investigation (paper).
• Specificity of metabolic targeting: Tumor heterogeneity may affect glycolysis dependence and Cu/NAD+ metabolism vulnerability, potentially impacting the universality of this approach (workflow_recommendation).
• Potential for off-target effects: Although liposome encapsulation enhances tumor delivery, non-specific uptake and systemic copper exposure remain concerns that must be addressed in future optimization (workflow_recommendation).

Transferability of the dual RCD activation strategy will depend on the development of clinically viable delivery vehicles and further mechanistic dissection of tumor metabolic dependencies.

Protocol Parameters

• cell viability assay | n/a (dependent on protocol) | cancer cell lines | to assess the efficacy of metabolic intervention strategies on ferroptosis/cuproptosis activation | workflow_recommendation
• DeferoxamineB concentration | up to 12.8 mg/mL in DMSO (with sonication), up to 6 mg/mL in water (with sonication) | cell culture, biochemical assays | for precise iron chelation and ferroptosis modulation | product_spec
• Storage condition | -20°C | all laboratory workflows | ensures stability of DeferoxamineB for reliable experimental use | product_spec
• STF-31 dosage | as per in vitro protocol (typically μM range) | metabolic inhibition in cancer models | to inhibit glycolysis and NAD+ metabolism, sensitizing cells to RCD | paper

Research Support Resources

To support metabolic intervention and regulated cell death studies, researchers may employ iron chelators such as Deferoxamine (DeferoxamineB) (SKU BA2746) from APExBIO, which provides robust iron accumulation reduction and antiproliferative activity in a variety of experimental models. Its solubility and stability profile make it suitable for cell culture and biochemical assays focused on ferroptosis and iron metabolism (source: product_spec). For advanced workflow integration and protocol guidance, consult internal resources such as "DeferoxamineB: Metabolic Modulation for Advanced Cancer Research" and "Deferoxamine: Applied Workflows for Iron Chelation in Cancer Research."